Journal: Chemical biology & drug design

Article Title: BSV163/DOPE-mediated TRAIL gene transfection acts synergistically with chemotherapy against cisplatin-resistant ovarian cancer.

doi: 10.1111/cbdd.14357

Figure Lengend Snippet: FIGURE 6 Flow cytometry analysis of the cell surface expression of DR4 and DR5 in cisplatin-sensitive (a,b) and -resistant (c) ovarian cancer lines after being treated with cisplatin (7.5 μM) for 24 h. cis, cisplatin treatment; Control, untreated cells. Differences between groups were analyzed using the Student's t-test. *Corresponding to a p value <.05; **corresponding to a p value <.01; #corresponding to a p value >.05 (non-significant). Representative images of the flow cytometry analysis are presented in Figure S6.

Article Snippet: Data were acquired on a BD Accuri C6 flow cytometer and analyzed with BD Accuri C6 software. (FITC)- conjugated anti- human DR4 and DR5 antibodies (Santa Cruz Biotechnology) were used at 4 μg/mL to examine the expression of DR in various cell lines with or without cisplatin treatment.

Techniques: Flow Cytometry, Expressing, Control

Journal: The World Journal of Men's Health

Article Title: Docetaxel Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Prostate Cancer Cells via Epigenetic Gene Regulation by Enhancer of Zeste Homolog 2

doi: 10.5534/wjmh.220073

Figure Lengend Snippet: Cell viability assay in prostate cancer cell lines after docetaxel and TRAIL treatment. Cells are exposed for 24 hours, and cell viability is determined using the MTT assay (A, B). Flow cytometry analysis of DU 145 shows that a combination of docetaxel 2 nM and TRAIL 100 ng/mL increases the proportion of Annexin V(+)/PI(+) (C). The expressions of EZH2 and DR4 in prostate cancer cell lines are shown. A WB assay is performed with specific antibodies against EZH2, DR4, DR5, and β-actin (D). After docetaxel treatment for 24 hours, the EZH2 level is decreased and the DR4 level is increased in DU 145 cells (E). The cell viability test is performed with a combination of docetaxel and TRAIL with or without the DR4 antagonist antibody (F). DR4: death receptor 4, DR5: death receptor 5, EZH2: enhancer of zeste homolog 2, ns: not significant, PI: propidium iodide, TRAIL: tumor necrosis factor-related apoptosis-inducing ligand, WB: western blot. *** p<0.001.

Article Snippet: TRAIL receptor inhibitors (neutralizing antibodies) and anti-human DR4 (ALX-804-297A; Enzo Life Sciences, Farmingdale, NY, USA) were always added 1 hour before the addition of TRAIL.

Techniques: Viability Assay, MTT Assay, Flow Cytometry, Western Blot

Journal: The World Journal of Men's Health

Article Title: Docetaxel Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Prostate Cancer Cells via Epigenetic Gene Regulation by Enhancer of Zeste Homolog 2

doi: 10.5534/wjmh.220073

Figure Lengend Snippet: Cell viability assay in prostate cancer cell lines after EZH2 inhibitors and TRAIL treatment. Cells are exposed for 48 hours. Cell viability is determined using the MTT assay (A, B). A WB assay is performed with specific antibodies against EZH2, DR4, DR5, and β-actin in prostate cancer cell lines (C-E). DR4: death receptor 4, DR5: death receptor 5, EZH2: enhancer of zeste homolog 2, TRAIL: tumor necrosis factor-related apoptosis-inducing ligand, WB: western blot. * p<0.05, ** p<0.01, *** p<0.001.

Article Snippet: TRAIL receptor inhibitors (neutralizing antibodies) and anti-human DR4 (ALX-804-297A; Enzo Life Sciences, Farmingdale, NY, USA) were always added 1 hour before the addition of TRAIL.

Techniques: Viability Assay, MTT Assay, Western Blot

Journal: The World Journal of Men's Health

Article Title: Docetaxel Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Prostate Cancer Cells via Epigenetic Gene Regulation by Enhancer of Zeste Homolog 2

doi: 10.5534/wjmh.220073

Figure Lengend Snippet: Expressions of EZH2 and E2F1 in DU 145 cells. WB assay shows decreases of EZH2 and E2F1 expressions after docetaxel treatment (A). Using knockdown of E2F1, the expressions of E2F1 and EZH2 are decreased (B), and TRAIL (100 ng/mL) treatment causes significant cell death in siE2F-1 DU 145 cells ( *** p<0.001) (C). DR4: death receptor 4, DR5: death receptor 5, EZH2: enhancer of zeste homolog 2, ns: not significant, TRAIL: tumor necrosis factor-related apoptosis-inducing ligand, WB: western blot.

Article Snippet: TRAIL receptor inhibitors (neutralizing antibodies) and anti-human DR4 (ALX-804-297A; Enzo Life Sciences, Farmingdale, NY, USA) were always added 1 hour before the addition of TRAIL.

Techniques: Western Blot

Journal: The World Journal of Men's Health

Article Title: Docetaxel Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Prostate Cancer Cells via Epigenetic Gene Regulation by Enhancer of Zeste Homolog 2

doi: 10.5534/wjmh.220073

Figure Lengend Snippet: MSP analysis is performed to evaluate the methylation status (A, B). ChIP assay is used to assess the relationship of EZH2 and the DR4 promoter in LNCap-LN3 and DU 145 cells (C). After docetaxel or DZNep treatment, the relationship of EZH2 and the promoter lesion of DR4 or DR5 is evaluated (D). ChIP: chromatin immunoprecipitation, DR4: death receptor 4, DR5: death receptor 5, EZH2: enhancer of zeste homolog 2, IgG: immunoglobulin G, MSP: methylation-specific polymerase chain reaction, ns: not significant, PCR: polymerase chain reaction. * p<0.05, ** p<0.01.

Article Snippet: TRAIL receptor inhibitors (neutralizing antibodies) and anti-human DR4 (ALX-804-297A; Enzo Life Sciences, Farmingdale, NY, USA) were always added 1 hour before the addition of TRAIL.

Techniques: Methylation, Chromatin Immunoprecipitation, Polymerase Chain Reaction